Edesa Biotech Inc
edesabiotech.comWhat Do They Do?
Develops drug candidates for inflammatory and immune-related diseases, including skin and respiratory conditions, and seeks pharmaceutical partners for their development or commercialization.
10-K for FY2025, filed Dec 12, 2025We are a biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our approach is to…View ↗
In Medical Dermatology we are developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune…View ↗
Our most advanced Respiratory drug candidate is EB05 (paridiprubart). Paridiprubart represents a new class of emerging therapies called…View ↗
Prioritize the development and commercialization of later-stage product candidates. Our goal is to obtain regulatory approval and…View ↗
Maximize the commercial potential of our product candidates via direct marketing or strategic arrangements. If our product candidates are…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q3 FY2026, filed Aug 13, 2026
−$5.4MView ↗
- ▲ +209% (Loss)
- vs −$1.7M in Q3 FY2025
Broader respiratory scope
The older report described the respiratory candidate for Covid-related hospitalized disease; the latest report also describes a study in ARDS patients with varied causes.
10-K for FY2022, filed Dec 16, 2022 10-K for FY2025, filed Dec 12, 2025Our most advanced drug candidate is EB05, a monoclonal antibody developed for acute and chronic disease indications that involve…View ↗
In June 2024, EB05 was selected through a competitive process by BARDA, part of the Administration for Strategic Preparedness and Response…View ↗
Different fibrosis focus
The earlier report described a planned systemic sclerosis study; the latest report says the pulmonary fibrosis program is being evaluated for next steps.
10-K for FY2022, filed Dec 16, 2022 10-K for FY2025, filed Dec 12, 2025In addition to EB05, we are developing product candidates for a number of chronic dermatological and inflammatory conditions. We recently…View ↗
We are seeking to advance additional product candidates as well as add new disease indications for current product candidates, and from…View ↗
Loading...
